Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LIXTW 
Lixte Biotechnology Holdings Inc (LIXTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LIXTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.8% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.49M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.37 | 52 Weeks Range 0.02 - 0.09 | Updated Date 06/21/2025 |
52 Weeks Range 0.02 - 0.09 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.14% | Return on Equity (TTM) -155.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 2527941 |
Shares Outstanding - | Shares Floating 2527941 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Lixte Biotechnology Holdings Inc
Company Overview
History and Background
Lixte Biotechnology Holdings Inc. was founded in 2005. The company is focused on discovering and developing novel therapies for cancer and other diseases. It aims to overcome the toxicity and resistance issues associated with conventional cancer therapies.
Core Business Areas
- Drug Development: Development of its lead compound, LB-100, and other potential drug candidates. Focus on clinical trials for various cancer types.
- Intellectual Property: Securing and maintaining patents related to its drug candidates and therapeutic methods.
Leadership and Structure
The company's leadership includes John S. Kovach, MD (Founder and CEO), and other executives with expertise in drug development and clinical research. The organizational structure comprises departments for research, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- LB-100: LB-100 is Lixte's lead clinical-stage product, a protein phosphatase 2A (PP2A) activator. It is currently being investigated in various cancer clinical trials. Currently, it has no market share as it's in clinical trials. Competitors include companies developing targeted therapies and other novel cancer treatments, such as Pfizer, Novartis, Roche, and Merck.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. There's a growing demand for novel cancer therapies with improved efficacy and safety profiles.
Positioning
Lixte Biotechnology Holdings Inc is a clinical-stage biotechnology company focused on developing novel therapies for cancer. Its competitive advantage lies in its PP2A activator technology, which has the potential to overcome resistance mechanisms in cancer cells.
Total Addressable Market (TAM)
The global oncology market is estimated to be over $200 billion annually. Lixte Biotechnology Holdings Inc is positioned to capture a portion of this market if its drug candidates are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Novel PP2A activator technology
- Experienced management team
- Clinical-stage product candidate
Weaknesses
- Limited financial resources
- Dependence on a single lead product candidate
- High risk associated with drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of clinical trials to additional cancer types
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- PFE
- NVS
- RHHBY
- MRK
Competitive Landscape
Lixte Biotechnology Holdings Inc faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its novel PP2A activator technology, but it must successfully navigate clinical trials and regulatory hurdles to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial progress and partnership opportunities.
Future Projections: Future growth projections depend on the successful development and commercialization of LB-100 and other drug candidates. Analyst estimates are variable due to the inherent uncertainty of drug development.
Recent Initiatives: Recent initiatives include advancing LB-100 through clinical trials and exploring potential partnerships.
Summary
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical company with a focus on novel cancer therapies. Its lead product, LB-100, is in clinical trials and holds potential for overcoming resistance in cancer cells. However, the company faces significant challenges, including limited financial resources and intense competition. Successful clinical trial outcomes and strategic partnerships are crucial for its future growth and sustainability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Yahoo Finance
- Various Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and there is no guarantee of success for Lixte Biotechnology Holdings Inc.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lixte Biotechnology Holdings Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2020-11-25 | CEO & Chairman Mr. Geordan G. Pursglove | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://lixte.com |
Full time employees 2 | Website https://lixte.com | ||
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.